137 related articles for article (PubMed ID: 7497578)
1. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Cummings J; Meikle I; Macpherson JS; Smyth JF
Cancer Chemother Pharmacol; 1995; 37(1-2):103-9. PubMed ID: 7497578
[TBL] [Abstract][Full Text] [Related]
2. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
Cummings J; Macpherson JS; Meikle I; Smyth JF
Biochem Pharmacol; 1996 Oct; 52(7):979-90. PubMed ID: 8831716
[TBL] [Abstract][Full Text] [Related]
3. Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
Cummings J; Meikle I; Macpherson JS; Smyth JF
J Chromatogr B Biomed Appl; 1996 Oct; 685(1):159-64. PubMed ID: 8930764
[TBL] [Abstract][Full Text] [Related]
4. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.
Meikle I; Cummings J; Macpherson JS; Hadfield JA; Smyth JF
Biochem Pharmacol; 1995 Jun; 49(12):1747-57. PubMed ID: 7598737
[TBL] [Abstract][Full Text] [Related]
5. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.
Meikle I; Cummings J; Macpherson JS; Smyth JF
Anticancer Drug Des; 1995 Oct; 10(7):515-27. PubMed ID: 7495476
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.
Cummings J; Meikle I; Macpherson JS; Smyth JF
Anticancer Drug Des; 1996 Jul; 11(5):367-82. PubMed ID: 8765530
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
Meikle I; Cummings J; Macpherson JS; Smyth JF
Br J Cancer; 1996 Aug; 74(3):374-9. PubMed ID: 8695351
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG).
Cummings J; Hadfield JA; Meikle I; McGown AT; Smyth JF
Anticancer Drugs; 1996 Aug; 7(6):636-41. PubMed ID: 8913431
[TBL] [Abstract][Full Text] [Related]
9. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
10. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
[TBL] [Abstract][Full Text] [Related]
12. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
[TBL] [Abstract][Full Text] [Related]
13. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
14. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
15. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Cummings J; Boyd G; Ethell BT; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
Biochem Pharmacol; 2002 Feb; 63(4):607-13. PubMed ID: 11992628
[TBL] [Abstract][Full Text] [Related]
16. Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
Noviello E; Aluigi MG; Cimoli G; Rovini E; Mazzoni A; Parodi S; De Sessa F; Russo P
Mutat Res; 1994 Nov; 311(1):21-9. PubMed ID: 7526171
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.
Schuurhuis GJ; Broxterman HJ; van der Hoeven JJ; Pinedo HM; Lankelma J
Cancer Chemother Pharmacol; 1987; 20(4):285-90. PubMed ID: 3500807
[TBL] [Abstract][Full Text] [Related]
18. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines.
Louie KG; Hamilton TC; Winker MA; Behrens BC; Tsuruo T; Klecker RW; McKoy WM; Grotzinger KR; Myers CE; Young RC
Biochem Pharmacol; 1986 Feb; 35(3):467-72. PubMed ID: 3947382
[TBL] [Abstract][Full Text] [Related]
19. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
20. Anion exchange chromatography for the determination of 5-methyl-2'-deoxycytidine: application to cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
Iglesias T; Espina M; Montes-Bayón M; Sierra LM; Blanco-González E
Anal Bioanal Chem; 2015 Mar; 407(9):2423-31. PubMed ID: 25142048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
